Nutrition and renal stone disease in space

Nutrition

Volumn 18, Issue 10, 2002, Pages 857-863

  Zerwekh, Joseph E ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Countermeasures; Nephrolithiasis; Nutrition; Space flight

Indexed keywords

CALCIUM OXALATE; CALCIUM PHOSPHATE; CITRIC ACID;

CALCIUM STONE; FOOD INTAKE; HUMAN; HYPERCALCIURIA; HYPERPHOSPHATEMIA; KIDNEY CONCENTRATING CAPACITY; METABOLISM; MICROGRAVITY; NEPHROLITHIASIS; NUTRITION; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPACE FLIGHT; STONE FORMATION; URIC ACID STONE; URINE PH; URINE VOLUME;

EID: 0036804535     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(02)00911-5     Document Type: Article

References (49)

1. Ranello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. J Nephrol. 13:(suppl 3):2000;S45.
2. Preminger G.M. Renal calculi pathogenesis, diagnosis and medical therapy. Semin Nephrol. 12:1992;200.
3. Clark J.Y., Thompson E.M., Optenberg S.A. Economic impact of urolithiasis in the United States. J Urol. 154:1995;2020.
4. Asplin J.R., Favus M.J., Coe F.L. Nephrolithiasis. Brenner E.M., Brenner and Rector's the kidney, 6th ed. Vol 2:2000;1774 WB Saunders, Philadelphia.
5. Pak C.Y.C., Waters O., Arnold L., et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria; supersaturation of urine with respect to monosodium urate. J Clin Invest. 59:1977;426.
6. Pak C.Y.C., Holt K. Nucleation and growth of brushite and calcium in urine of stone-formers. Metabolism. 25:1976;665.
7. Zerwekh J.E., Holt K., Pak C.Y.C. Attenuation by the urate salts of the inhibitory effect of naturally occurring urinary macromolecules on calcium oxalate nucleation and crystal growth. Kidney Int. 23:1983;838.
8. Pak C.Y.C., Ohata M., Lawrence E.C., Snyder W. The hypercalciurias causes, parathyroid functions and diagnostic criteria. J Clin Invest. 54:1974;387.
9. Curhan G.C., Willett W.C., Rimm E.B., Stampfer M.J. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 328:1993;833.
10. Pak C.Y.C., Peterson R., Poindexter J.R. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. J Urol. 165:2001;378.
11. Wilson D.M., Smith L.H., Erickson S.B., Torres V.E., Liedtke R.R. Renal oxalate handling in normal subjects and patients with idiopathic renal lithiasis primary and secondary hyperoxaluria. Walker V.R., Sutton R.A.L., Cameron E.C.B., Pak C.Y.C., Rogertson W.G., Urolithiasis. 1989;453 Plenum, New York.
12. Coe F.L., Moran E., Kavalach A.G. The contribution of dietary purine over consumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis. 29:1976;793.
13. Coe F.L. Uric acid and calcium oxalate nephrolithiasis. Kid Int. 24:1983;392.
14. Alvarez Arroyo M.V., Traba M.L., Papado A. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones. Urol Int. 48:1992;342.
15. McCarron D.A., Rankin L.I., Bennett W.M., et al. Urinary calcium excretion at extremes of sodium intake in normal man. Am J Nephrol. 1:1981;84.
16. Robertson W.G. Diet and calcium stones. Miner Electrolyte Metab. 127:1987;593.
17. Prien E.L. The riddle of urinary stone disease. JAMA. 216:1971;503.
18. Robertson W.G., Peacock M. The pattern of urinary stone disease in Leeds and in the United Kingdom in relation to animal protein intake during the period 1960-1980. Urol Invest. 37:1982;394.
19. Borghi L., Schianchi T., Guerra A., et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 346:2002;77.
20. Walser M., Browder A.A. Ion association III. The effect of sulfate infusion on calcium excretion. J Clin Invest. 38:1959;1404.
21. Baggio B., Gambaro G. Abnormal arachidonic acid content of membrane phospholipids-the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant. 14:1999;553.
22. Baggio B., Gambaro G., Zambon S., et al. Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol. 7:1996;613.
23. Buck A.C., Davies R.L., Harrison T. The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of hypercalciuria. J Urol. 146:1991;188.
24. Henriquez-LaRoche C., Rodriguez-Iturbe B., Herrera J., Parra G. Increased urinary excretion of prostaglandin E in patients with idiopathic hypercalciuria. Clin Sci. 75:1988;581.
25. Hess B., Ackermann D., Essig M., et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers role of protein intake. J Clin Endocrinol Metab. 80:1995;1916.
26. Baggio B., Budakovic A., Angela M. Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis. Kidney Int. 58:2000;1278.
27. Buck A.C., McLeod M.A., Sampson W.F. The role of renal eicosanoid metabolism in the pathogenesis of renal stone formation. Rodgers A.L., Hibbert B.E., Hess B., et al. Urolithiasis 2000. 2000;640 University of Capetown Rodebosch, Capetown, South Africa.
28. Leach C.S., Rambaut P.C. Biochemical response of the Skylab crewman an overview. Johnston R.S., Dietlein L.F., Biomedical results from Skylab, NASA SP-377. 1977;204 National Aeronautics and Space Administration, Washington, DC.
29. Leach C.S., Rambaut P.C. Biomedical observations of long-duration manned orbital space flight. J Am Med Women Assoc. 30:1975;153.
30. Whedon D., Lutwak L., Rambaut P.C., et al. Effects of weightlessness on mineral metabolism metabolic studies on Skylab orbital space flights. Calcif Tissue Res. 21:1976;423.
31. Nicogossian A.E. Overall physiological response to space flight. Nicogossian A.E., Huntoon C.L., Pool S.L., Space physiology and medicine. 2nd ed. 1989;139 Lea and Febiger, Philadelphia.
32. Whedon D., Lutwak L., Rambaut P.C., et al. Mineral and nitrogen metabolic studies, experiment M071. Johnston R.S., Dietlein L.F., Biomedical results from Skylab, NASA SP-377. 1977;164 National Aeronautics and Space Administration, Washington, DC.
33. Whitson P.A., Pietrzyk R.A., Pak C.Y.C., Cintron N.M. Alterations in renal stone risk factors after space flight. J Urol. 150:1993;803.
34. Whitson P.A., Pietrzyk R.A., Pak C.Y.C. Renal stone risk assessment during space shuttle flights. J Urol. 158:1997;2305.
35. Whitson P.A., Pietrzyk R.A., Morukov B.V., Sams C.F. The risk of renal stone formation during and after long duration space flight. Nephron. 89:2001;264.
36. Hwang T.I.S., Hill K., Schneider V., Pak C.Y.C. Effect of prolonged bed rest on the propensity for renal stone formation. J Clin Endocrinol Metab. 66:1988;109.
37. Ruml L.A., Dubois S.K., Roberts M.L., Pak C.Y.C. Prevention of hypercalciuria and stone-forming propensity during prolonged bed rest by alendronate. J Bone Min Res. 10:1995;655.
38. LeBlanc A.D., Schneider V.S., Evans H.J., Engelbretson D.A., Krebs J.M. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Min Res. 5:1990;843.
39. Zerwekh J.E., Ruml L.A., Gottschalk F., Pak C.Y.C. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Min Res. 13:1998;1594.
40. Messa P., Mioni G., Paganin L., et al. Urinary citrate, bone resorption and intestinal alkali absorption in stone formers with fasting hypercalciuria. Scan Microsc. 8:1994;531.
41. Lindberg J., Harvey J., Pak C.Y.C. Effects of magnesium citrate and magnesium oxide on crystallization of calcium salts in urine changes produced by food-magnesium interaction. J Urol. 143:1990;248.
42. Pak C.Y.C., Koenig K., Khan R., Haynes S., Padalino P. Physicochemical action of potassium-magnesium citrate in nephrolithiasis. J Bone Min Res. 7:1992;281.
43. Ettinger B., Pak C.Y.C., Citron J.T., et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 158:1997;2069.
44. Sakhaee K., Nicar M., Hill K., Pak C.Y.C. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 24:1983;348.
45. Lemann J. Jr, Gray R.W., Pleuss J.A. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int. 35:1989;688.
46. Sebastian A., Harris S.T., Ottaway J.H., Todd K.M., Curtis Morris R. Jr. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med. 330:1994;1776.
47. Barzel U.S. Alkali therapy in immobilization osteoporosis. Israel J Med Sci. 7:1971;499.
48. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments United States 1997. Vital and health statistics. Series 13, No. 143:November 1999;NCHS, CDC, DHHS, Atlanta, GA.
49. 1999 National hospital discharge survey: annual summary with detailed diagnoses and procedures data. Vital and health statistics. Series 13, No. 151:September 2001;NCHS, CDC, DHHS, Atlanta, GA.